Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
about
Acupuncture for treatment-related side effects in women with breast cancerTreatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerCurrent medical treatment of estrogen receptor-positive breast cancerManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentManaging aromatase inhibitors in breast cancer survivors: not just for oncologistsAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Natural compounds with aromatase inhibitory activity: an update.Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trialCerebral venous thrombosis in a breast cancer patient taking tamoxifen: Report of a case.Targeted therapies for breast cancer.Male breast cancer: an update in diagnosis, treatment and molecular profilingBreast cancer incidence and mortality in a transitioning Chinese population: current and future trends.Psychotropic medication during endocrine treatment for breast cancer.The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trialBlockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancerOptimal management of bone metastases in breast cancer patients.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know.Aromatase inhibitors for ovulation induction and ovarian stimulation.Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration.High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.
P2860
Q24202994-C11F1134-2BE1-426D-84A0-0E83D2D5C4C3Q26741153-F5AE9CA2-17BB-43C1-A43A-2BE0645BB62BQ26746212-E3E5D2A2-4746-4C5F-94FA-DB37D773F853Q26775361-93C15FA8-17A9-4CBC-86FC-4A2CE90A8E2DQ26785496-88E5DF6B-9307-44C0-9CAF-7CA03B32A661Q26795751-B4A78634-75FF-493B-A7EE-634A1546E8FCQ26995549-0E12BD6C-3B71-4BE8-84BC-F4CE4549BC8FQ27343148-DDE14D80-7ED6-43FF-8DCA-B81EE6088314Q28076777-1B95CC23-F33F-4340-A920-19BE0B214E84Q30317067-BA26EBC4-E8DD-4945-A341-7DD5A88F4688Q30318823-F9998A8E-772C-4805-9A91-D982188B49AFQ33584169-BA9B8C3E-09A5-463E-8F20-3D049422DD53Q33664433-10AC7F59-EFDC-4CC9-BDE2-B5B4874EB3D7Q33884184-2CAC8507-E1DB-47C1-B07A-74D3879E10FEQ34042768-3C8353C6-4D3F-4ED8-8145-268E5E483FA5Q34249437-25739E3F-837C-46B8-8890-8FB3EAB964BDQ34720114-5B7DE26D-E1D9-49D4-832E-72793C81E541Q34991931-D0D138D8-6A44-4643-BDF3-3CC64E869A59Q35101978-63775E31-C4A2-43F2-826A-71697E8E7B00Q35372584-DFF1F039-8E93-4497-A529-CE220D9683E7Q35660943-755EC60B-58BA-40EC-AC55-E9D62D166651Q35677680-49E6D376-624A-4AE7-85B4-A59AD4250B31Q35989795-CEBC2228-6E1E-40FB-973F-AF18592DA97BQ36087210-108F21DA-FD27-48B3-9E63-793CACE1855BQ36162366-1809B647-542A-42E6-A84B-F77931B86B5DQ36902056-0C3180E7-7076-4196-88E4-36E595EE31DFQ37025619-4D109B54-9209-4810-933F-F700A0951E8EQ37214089-B64BDD52-0AA5-4F66-BAED-B935484E5F4AQ37355487-01D5E035-C846-4F3A-8AF0-D35BA35F44B0Q37570653-D81889B9-C33C-473C-B16C-7C392C39FF4CQ37615072-E24A4100-EE2D-4239-ADEA-04235F301355Q37657782-4B7AEEFD-2DDB-449D-BAB2-3D2ED3FF2661Q37671187-5110BBE3-502B-416C-B457-BD87EDF123FCQ37862363-3F6AA167-A4BB-4AA0-A60F-977E7709F3F8Q38264861-BAEEC088-854A-4DC4-B352-66FC782E50E5Q40233516-058245CC-4837-41EA-AA26-B38DE44CE4BCQ41521650-A6BF66BA-1717-4E22-BA36-8C1369F9D93FQ44783447-4F9E489A-ABFD-492F-9149-10436D31B00BQ47134924-70264042-C7FB-49BF-B11F-2525508EF9C4Q55427632-CD543B27-1313-4103-96A0-3AFC75A9FDE3
P2860
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@ast
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en-gb
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@nl
type
label
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@ast
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en-gb
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@nl
prefLabel
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@ast
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en-gb
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@nl
P2093
P2860
P3181
P1476
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
@en
P2093
Claire Dawson
David Lawrence
Judith Bliss
Lorna Gibson
P2860
P3181
P356
10.1002/14651858.CD003370.PUB3
P577
2009-10-07T00:00:00Z